Video

Dr. Furman on FDA-Approved BTK Inhibitors in B-Cell Malignancies

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Richard R. Furman, MD, a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology and director of the CLL Research Center at Weill Cornell Medical College, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Currently, 3 FDA-approved BTK inhibitorsare available for use in the United States, all of which work by covalently modifying the BTK enzyme, says Furman. Ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) covalently bind to the cysteine at the position 481 and block the BTK pocket, thus rendering the enzyme ineffective, explains Furman.

Currently, ibrutinib is approved for use in chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, mantle cell lymphoma (MCL), and marginal zone lymphoma. Acalabrutinib received regulatory approval for use in CLL and MCL, and zanubrutinib is only approved for use in the MCL space.

All 3 drugs have similar benefits and investigators expect that their activity will be demonstrated or confirmed in the same histologies as ibrutinib has, concludes Furman.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity